SU-E-J-99: Multi-Atlas Based Auto-Segmentation of Low-Risk Clinical Target Volume (CTV) for Head-and-Neck Radiotherapy

2011 ◽  
Vol 38 (6Part8) ◽  
pp. 3465-3465
Author(s):  
J Yang ◽  
R Williamson ◽  
A Garden ◽  
D Rosenthal ◽  
Y Zhang ◽  
...  
Keyword(s):  
Head And Neck ◽  
Clinical Target Volume ◽  
Target Volume ◽  
Low Risk ◽  
Head And Neck Radiotherapy

Auto-segmentation of low-risk clinical target volume for head and neck radiation therapy

2014 ◽  
Vol 4 (1) ◽  
pp. e31-e37 ◽  
Author(s):  
Jinzhong Yang ◽  
Beth M. Beadle ◽  
Adam S. Garden ◽  
Brandon Gunn ◽  
David Rosenthal ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck ◽  
Clinical Target Volume ◽  
Target Volume ◽  
Low Risk ◽  
Head And Neck Radiation

scholarly journals Synergies Radiotherapy-Immunotherapy in Head and Neck Cancers. A New Concept for Radiotherapy Target Volumes-“Immunological Dose Painting”

Medicina ◽  
2020 ◽  
Vol 57 (1) ◽  
pp. 6
Author(s):  
Camil Ciprian Mireştean ◽  
Anda Crişan ◽  
Călin Buzea ◽  
Roxana Irina Iancu ◽  
DragoşPetru Teodor Iancu
Keyword(s):  
Immune System ◽  
Synergistic Effect ◽  
Head And Neck ◽  
Multimodal Treatment ◽  
Clinical Target Volume ◽  
Locally Advanced ◽  
Target Volume ◽  
Head And Neck Cancers ◽  
Dose Painting ◽  
Target Volumes

The combination of immune checkpoint inhibitors and definitive radiotherapy is investigated for the multimodal treatment of cisplatin non-eligible locally advanced head and neck cancers (HNC). In the case of recurrent and metastatic HNC, immunotherapy has shown benefit over the EXTREME protocol, being already considered the standard treatment. One of the biggest challenges of multimodal treatment is to establish the optimal therapy sequence so that the synergistic effect is maximal. Thus, superior results were obtained for the administration of anti-CTLA4 immunotherapy followed by hypofractionated radiotherapy, but the anti-PD-L1 therapy demonstrates the maximum potential of radio-sensitization of the tumor in case of concurrent administration. The synergistic effect of radiotherapy–immunotherapy (RT–IT) has been demonstrated in clinical practice, with an overall response rate of about 18% for HNC. Given the demonstrated potential of radiotherapy to activate the immune system through already known mechanisms, it is necessary to identify biomarkers that direct the “nonresponders” of immunotherapy towards a synergistic RT–IT stimulation strategy. Stimulation of the immune system by irradiation can convert “nonresponder” to “responder”. With the development of modern techniques, re-irradiation is becoming an increasingly common option for patients who have previously been treated with higher doses of radiation. In this context, radiotherapy in combination with immunotherapy, both in the advanced local stage and in recurrent/metastatic of HNC radiotherapy, could evolve from the “first level” of knowledge (i.e., ballistic precision, dose conformity and homogeneity) to “level two” of “biological dose painting” (in which the concept of tumor heterogeneity and radio-resistance supports the need for doses escalation based on biological criteria), and finally to the “third level“ ofthe new concept of “immunological dose painting”. The peculiarity of this concept is that the radiotherapy target volumes and tumoricidal dose can be completely reevaluated, taking into account the immune-modulatory effect of irradiation. In this case, the tumor target volume can include even the tumor microenvironment or a partial volume of the primary tumor or metastasis, not all the gross and microscopic disease. Tumoricidal biologically equivalent dose (BED) may be completely different from the currently estimated values, radiotherapy treating the tumor in this case indirectly by boosting the immune response. Thus, the clinical target volume (CTV) can be replaced with a new immunological-clinical target volume (ICTV) for patients who benefit from the RT–IT association (Image 1).

scholarly journals Evaluation of interfraction patient setup errors for image-guided prostate and head-and-neck radiotherapy using kilovoltage cone beam and megavoltage fan beam computed tomography

2013 ◽  
Vol 12 (4) ◽  
pp. 334-343 ◽  
Author(s):  
X. Sharon Qi ◽  
Sutan Wu ◽  
Francis Newman ◽  
X. Allen Li ◽  
Angie Y. Hu
Keyword(s):  
Computed Tomography ◽  
Head And Neck ◽  
Target Volume ◽  
Cone Beam ◽  
Setup Errors ◽  
Image Guided Radiotherapy ◽  
Image Guided ◽  
Significant Difference ◽  
Late Stages ◽  
Head And Neck Radiotherapy

AbstractPurposeTo analyse interfraction setup using two different image guidance modalities for prostate and head-and-neck (H&N) cancer treatment.Materials and methodsSeventy-two prostate and 60 H&N cancer patients, imaged with kilovoltage cone beam computed tomography (KVCBCT) or megavoltage fan beam computed tomography (MVFBCT), were studied retrospectively. The daily displacements in mediolateral (ML), craniocaudal (CC) and anteroposterior (AP) dimensions were investigated. The setup errors were calculated to determine the clinical target volume to planning target volume (CTV-to-PTV) margins.ResultsBased on 1,606 KVCBCT and 2,054 MVFBCT scans, average interfraction shifts in ML, CC and AP direction for H&N cases were 0·5 ± 1·5, −0·3 ± 2·0, 0·3 ± 1·7 mm using KVCBCT, 0·2 ± 1·9, −0·2 ± 2·4 and 0·0 ± 1·7 mm using MVFBCT. For prostate cases, average interfraction displacements were −0·3 ± 3·9, 0·2 ± 2·4, 0·4 ± 3·8 mm for MVFBCT and −0·2 ± 2·7, −0·6 ± 2·9, −0·5 ± 3·4 mm for KVCBCT. The calculated CTV-to-PTV margins, if determined by image-guided radiotherapy (IGRT) data, were 5·6 mm (H&N) and 7·8 mm (prostate) for MVFBCT, compared with 4·8 mm and 7·2 mm for KVCBCT. We observed no statistically significant difference in daily repositioning using KVCBCT and MVFBCT in early, middle and late stages of the treatment course.ConclusionIn the absence of IGRT, the CTV-to-PTV margin determined using IGRT data, may be varied for different imaging modalities for prostate and H&N irradiation.

On the Delineation of the Gross Tumor Volume and Clinical Target Volume for Head and Neck Squamous Cell Carcinomas

2001 ◽  
Vol 87 (3) ◽  
pp. 152-161 ◽  
Author(s):  
Giuseppe Sanguineti ◽  
Franca Foppiano ◽  
Michela Marcenaro ◽  
Federico Roncallo ◽  
Renzo Corvò ◽  
...  
Keyword(s):  
Head And Neck ◽  
Squamous Cell ◽  
Gross Tumor Volume ◽  
Clinical Target Volume ◽  
Tumor Volume ◽  
Target Volume ◽  
Squamous Cell Carcinomas

A population-based atlas and clinical target volume for the head-and-neck lymph nodes

2004 ◽  
Vol 59 (5) ◽  
pp. 1301-1311 ◽  
Author(s):  
Ian Poon ◽  
Nancy Fischbein ◽  
Nancy Lee ◽  
Pamela Akazawa ◽  
Ping Xia ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Head And Neck ◽  
Clinical Target Volume ◽  
Target Volume ◽  
Population Based ◽  
Neck Lymph Nodes
Sign in / Sign up

Export Citation Format

Share Document